“
Metformin remains the drug of choice
for first-line therapy
”
1
…
“
should
be initiated concurrent with lifestyle
intervention at diagnosis
”
2
“
Consider extended-release tablets when
GI side effects prevent continuation of
metformin therapy
”
3
Society for Endocrinology,Metabolism
andDiabetes of SouthAfrica
Merck Pharma Customer Call Centre 08611 MERCK or 08611 63725.
Start
Right…
Low incidence of GI side effects
4
Powerful glycaemic control
5
Significantly improved adherence to treatment
6
No weight gain
7
For newly diagnosed Type 2 Diabetes patients
and those intolerant to immediate-release metformin
due to gastrointestinal side effects
NEW
CONSENSUS
References:1.
IDFClinicalGuidelinesTaskForce.GlobalGuidelinesforType2diabetes.Brussels: InternationalDiabetesFederation,2005.
2.
NathanDM,BuseJB,DavidsonMB,
etal.
Managementofhyperglycaemia inType2diabetes:aconsensusalgorithmforthe initiation
andadjustmentoftherapy. Aconsensusstatement fromtheAmericanDiabetesAssociationandtheEuropeanAssociation fortheStudyofDiabetes.
Diabetologica
2006;49(8):1711-1721.
3.
SEMDSAGuidelines forDiagnosisandManagementofType2DiabetesMellitus
forPrimaryHealthCare.
JEMDSA
2009;14(1):55-58.
4.
BlondeL,DaileyGE, JabbourSA,ReasnerCA,MillsDJ.Gastrointestinal tolerabilityofGlucophage
®
XRextended-release tabletscompared to immediate-releaseGlucophage
®
tablets- resultsofa retrospectivecohort
study.
CurrMedResOpin
2004
;
20
:
565-572.
5.
FujiokaK,
etal
.Efficacy,dose-response relationshipandsafetyofonce-dailyextended-releasemetformin (Glucophage
®
XR) in type2diabeticpatientswith inadequateglycemiccontroldespiteprior treatmentwithdietand
exercise:resultsfromtwodouble-blind,placebo-controlledstudies.
CurrentTherapeutics
Vol25,No2:2003
.
6.
DonnellyLA,MorrisAD,PearsonER.Adherence inpatientstransferredfrom immediate-releasemetformintoasustainedreleaseformulation:apopulation-based
study.
Diabetes,ObesityandMetabolism
2009;11:338-342.
7.
FujiokaK,JoyalS,BruceS.Type2Diabetespatientsswitched from immediate-releasemetforminbid toanextended releaseqd formulation ina randomized,controlled trialmaintainedcomparableglycaemic
control.
ClinTher
2003;25:515-529.
S3
GLUCOPHAGE
®
XR500mgModifiedReleaseTablet.EachModifiedReleaseGLUCOPHAGE
®
XR tabletcontains500mgmetforminhydrochloride.Reg.No.A39/21.2/0027.
MERCK (PTY)LTD,Reg.no.:1970/004059/07.1FrieslandDrive,LongmeadowBusinessEstateSouth,Modderfontein1645.Tel:0113725000Fax:0113725252.
123838
Merck Serono CardioMetabolic Care
